Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMIDs

Author： Ocio Enrique M Mateos Maria-Victoria San-Miguel Jesus F

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.8, 2012-08, pp. : 1075-1087

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Renin inhibitors as novel treatments for cardiovascular disease

By Maibaum Jürgen Feldman David L

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 5, 2003-05 ,pp. : 589-603

Informa Healthcare

Access to resources Recommend Favorite

Proteasome inhibitors: possible novel therapeutic strategy for ischemia–reperfusion injury?

By Kandilis Apostolos N Karidis Nikolaos P Kouraklis Gregory Patsouris Efstratios Vasileiou Ioanna Theocharis Stamatios

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 67-80

Informa Healthcare

Access to resources Recommend Favorite

PPAR-γ inhibitors as novel tubulin-targeting agents

By Schaefer Katherine L

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 7, 2007-06 ,pp. : 923-926

Informa Healthcare

Access to resources Recommend Favorite

Cyclin-dependent kinase inhibitors: novel anticancer agents

By Mani S. Wang C. Wu K. Francis R. Pestell R.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 8, 2000-08 ,pp. : 1849-1870

Informa Healthcare

Access to resources Recommend Favorite

Histone deacetylase inhibitors: novel anticancer agents

By Saunders N.A. Popa C. Serewko M.M. Jones S.J. Dicker A.J. Dahler A.L.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 10, 1999-10 ,pp. : 1611-1621

Informa Healthcare

Access to resources Recommend Favorite